Glaxo: A History to 1962
Cambridge University Press, Nov 26, 1992 - Business & Economics - 406 pages
Glaxo is the world's second largest pharmaceutical multinational. This study of the company, from its beginnings to 1962, is based on unprecedented and unparalleled archival access to the company records. It gives a detailed account of the global operations of Glaxo, and describes not only the evolution of this international business, but studies its research and development programmes, its products, and its marketing and management. It is a story of power, money and drugs, the first comprehensive study of a UK-based drugs company and the only scholarly study yet written of a front-ranking world company.
What people are saying - Write a review
We haven't found any reviews in the usual places.
The Nathans and proprietary foods 19031918
Boom and depression for Glaxo and the Nathans
Glaxo Laboratories Ltd
Early internationalisation and the growth of overseas
Pharmaceuticals triumphant 19461962
a strategy of science?
North and South America
India and Pakistan
Australia and New Zealand
Glaxo in Europe
The development and commercial exploitation
Glaxo Laboratories and the international development
advertising agreement Alec Nathan Allen & Hanburys American antibiotics Argentina Australia Barnard Castle Birchley Board Britain bulk Canada Canadian cent chemical chemists commercial Committee company's competition competitors cortisone cost dried milk drugs early Ergosterol established export factory Farex fermentation Fred Nathan Gent Glaxo Archives Glaxo Baby Glaxo department Glaxo Laboratories Glaxo powder Glaxo's research Greenford griseofulvin Harvalias Herbert Palmer Ibid important increased India investment Italy Jephcott Jephcott to Palmer Joseph Nathan licences managing director manufacture Merck milk powder Ministry multinational Nathan & Co November operations organisation Ostelin overseas subsidiaries Pacey packing Pakistan parent company patent penicillin pharmaceutical companies pharmaceutical industry plant Port Fairy post-war problems profit programme proprietary reported representatives research and development result royalties Schering selling shares South Africa Squibb staff streptomycin supplies Tizard trade turnover vaccine vitamin vitamin D Wadeville Wilkins Zealand